A phase I study of AEG35156 given as a 2 hour intravenous infusion in combination with docetaxel in patients with solid tumours.

Trial Profile

A phase I study of AEG35156 given as a 2 hour intravenous infusion in combination with docetaxel in patients with solid tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs AEG 35156 (Primary) ; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jan 2012 Actual end date changed from (1 Mar 2009) to (1 Jan 2012) as reported by ClinicalTrials.gov.
    • 16 Sep 2011 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 16 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top